ARGX Stock Recent News

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response

With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.

Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.

argenx remains a dominant player in the anti-FcRn market, with Vyvgart approved for gMG, CIDP, and ITP in Japan. The ALKIVIA trial aims to expand Vyvgart's use in myositis, a rare autoimmune disease affecting at least 45,000 people in the U.S. Efgartigimod's FcRn inhibition reduces pathogenic IgG autoantibodies, showing potential across multiple autoimmune diseases.

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced publication in The Lancet Neurology of the pivotal ADHERE Study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system.

Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.

Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation biotech stocks could offer. But with so many names and new research coming out every day, it can be difficult to find where to start.

ARGX, VZLA, and SBFG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2024.

SBFG, APOG, ARGX, VZLA and SVM have been added to the Zacks Rank #1 (Strong Buy) List on July 31, 2024.